| Expression pattern: |
DN |
| Associated gene: |
IGF2BP1, MYC, FSCN1 |
| Associated microRNA: |
miR-636 |
| Biological function: |
Suppresses bladder cancer progression by inhibiting proliferation, migration, invasion, and metastasis. |
| Molecular mechanism: |
circPTPRA binds IGF2BP1 (KH3/KH4 domains) and blocks IGF2BP1 recognition/binding to m6A-modified target mRNAs (e.g., MYC and FSCN1), reducing their mRNA stability. |
| Biological pathway or process: |
proliferation (inhibits); migration (inhibits); invasion (inhibits); metastasis (inhibits); cell cycle (inhibits); mRNA stability (inhibits); m6A modification (other) |
| Detected method: |
Q
S
|
| Validation methods: |
RT-qPCR; RNA-seq; Bioinformatics Analysis; Clinical Sample Validation; Survival Analysis; RIP (RNA Immunoprecipitation); RNA Pull-Down; Luciferase Reporter Assay; Transfection; Western Blot; Cell Cycle Assay; Transwell Assay; FISH / smFISH; IF (Immunofluorescence); IHC (Immunohistochemistry); Actinomycin D / DRB Stability Assay; In Vivo Animal Model |
| Clinical significance: |
Low level of circPTPRA was significantly associated with poor overall survival of 64 patients with BC. |
| Description: |
circPTPRA is down-regulated in bladder cancer and functions as a tumor suppressor. It binds the m6A reader IGF2BP1 (via KH3/KH4), interferes with IGF2BP1 recognition of m6A-modified RNAs, and reduces stability/expression of oncogenic targets such as MYC and FSCN1, thereby inhibiting proliferation, migration, invasion, and metastasis. |
| Confidence score: |
0.8554 |